Development of IPS report cell lines expressing hibit atspecified heal-related genes
Ended Purchase Order Awarded Last action
- Contract number
- 75N95020P00676
- Awardee
-
Synthego Corporation UEI RNDBNJAKTJC9
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $223,632
Award facts
- Opportunity
-
- Development of iPS report cell lines expressing HiBiT at specified HEAL-related genes Solicitation · 75N95020Q00328 · Posted Sep 10, 2020
- Contract value 100% obligated
- $223,632.35 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Redwood City, CA 94063, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$11,518 | |
| Other Administrative Action | $0 | |
| Original award | $235,150 |
About this award
The National Institute on Drug Abuse awarded a $223,632 firm fixed-price purchase order to Synthego Corporation on September 23, 2020, for the development of induced pluripotent stem (IPS) cell lines expressing HiBiT at specified health-related genes. The contract, which involved no small business set-aside, was performed in Redwood City, California, with an ultimate completion date of March 31, 2021. This award represented the de-obligation of unexpended and expiring fiscal year 2020 funding in accordance with federal appropriations law, ensuring the timely utilization of funds before their September 30, 2025 period of availability closure.
Synthego Corporation, a self-certified small disadvantaged business specializing in genome engineering solutions and CRISPR-based gene editing services, has established itself as a key provider of custom cell line development and genetic engineering tools for federal biomedical research initiatives. The company's expertise in advanced genetic engineering and prior track record of over 30 federal prime contracts—predominantly with National Institutes of Health institutes and other agencies including the Department of Veterans Affairs—positioned it to deliver the specialized cell line engineering services required by NIDA's research objectives in drug abuse and addiction studies.
Quick answers
Who was awarded contract 75N95020P00676?
75N95020P00676 was awarded to Synthego Corporation by National Institute on Drug Abuse (National Institutes of Health) on September 23, 2020.
How much is contract 75N95020P00676 worth?
The government has obligated $223,632 on 75N95020P00676.
Was contract 75N95020P00676 competed?
The extent of competition for 75N95020P00676 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award